Skip to main content

Main menu

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers

User menu

  • Subscriptions
  • Alerts
  • Log in

Search

  • Advanced search
British Journal of General Practice
Intended for Healthcare Professionals
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
  • Subscriptions
  • Alerts
  • Log in
  • Follow bjgp on Twitter
  • Visit bjgp on Facebook
  • Blog
  • Listen to BJGP podcast
  • Subscribe BJGP on YouTube
Intended for Healthcare Professionals
British Journal of General Practice

Advanced Search

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
Life & Times

The impact on general practice of prescribing assisted dying drugs

Claud Regnard, Carol Davis, Katherine Sleeman, Philip Williams and Ana Worthington
British Journal of General Practice 2021; 71 (712): 516. DOI: https://doi.org/10.3399/bjgp21X717605
Claud Regnard
Palliative Medicine, St. Oswald’s Hospice, Newcastle-upon-Tyne. Email:
Roles: Honorary consultant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: claudregnard@stoswaldsuk.org
Carol Davis
University Hospital Southampton NHS Foundation Trust.
Roles: Consultant in Palliative Medicine and Clinical Lead for End-of-Life Care
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Sleeman
National Institute for Health Research Clinician Scientist and Honorary Consultant in Palliative Medicine, Kings College London.
Roles: Laing Galazka Professor of Palliative Care
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip Williams
Nettleham Medical Practice, Lincolnshire.
Roles: GP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Worthington
Keble College, University of Oxford.
Roles: Postgraduate Student
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info
  • eLetters
  • PDF
Loading

Assisted dying is the topic of much debate by societies and governments today. The issue of the drugs used to assist patients in dying, and their safety and efficacy, is rarely discussed. This has important implications for UK general practice if assisted dying is legalised and incorporated into existing health care.

Until 2016, doctors in Oregon in the US prescribed one of two oral barbiturates to produce unconsciousness and death. Since the European Commission restricted the sale of these barbiturates to the US due to their use in judicial executions, the availability of these drugs has become increasingly scarce. This has compelled doctors to prescribe experimental drug combinations to bring about patient death.

For example, in 2020, 87% of assisted deaths in Oregon have used a drug combination called ‘DDMA’, a mixture of a benzodiazepine, a cardiac glycoside, an opioid, and an antidepressant, with some also receiving a barbiturate. In Canada, oral protocols vary from a barbiturate plus antiemetic, to combinations of a benzodiazepine, barbiturate, opioid, and a hypnotic. Oregon has used four different protocols in the last 7 years.

ADVERSE EVENTS

The safety and efficacy of previous and current oral assisted dying drug combinations is not known. There have been few well-conducted studies, some several decades old. Using multiple drugs multiplies the risk of adverse events, especially when they are used in high doses in patients with no previous exposure. Reported adverse effects include vomiting, myoclonus, and a prolonged dying process of up to 47 hours.

In 2020, the official Oregon report stated that, compared with single barbiturates, ‘All drug combinations have shown longer median times until death.’ The physical and psychological impact of a prolonged assisted death on the patient has not been investigated, and we do not know the impact of such deaths on the grieving process of friends and relatives.

Figure

Oregon states the complication rate for assisted deaths in 2020 was 6.9% (5 out of the 72 cases where this information was known), but this does not include prolonged deaths, and information on complications was unknown in 70.6% (173 out of 245) of deaths. Reports by the Canadian Association of MAID Assessors and Providers acknowledge that individuals may experience a range of complications with oral assisted dying drugs. Drugs are normally required to undergo a formal approval process that demands direct measurements of patient outcomes. Using death as the only endpoint takes no account of how quick this was or what complications occurred on the way. Medical history is littered with examples of treatments that were widely used and promoted but later found to be harmful. Thalidomide was approved by 17 countries including the UK, until its harmful effects were recognised. Assisted dying drugs have less published data on patient and carer outcomes than thalidomide.

UNWILLING DOCTORS

If assisted dying is legalised in the bills currently before the Westminster and Holyrood parliaments, GPs will have to consider prescribing untested drugs or drug combinations. This could breach General Medical Council prescribing guidance that a doctor ‘must be satisfied that the drugs serve your patient’s needs.’ In addition, the British Medical Association’s 2020 survey on assisted dying showed a majority of UK licensed doctors (47% versus 34%) were unwilling to prescribe oral drugs for assisted dying.

Unless assisted dying is practised separately from health care, this will pose challenges for working relationships in general practice. This assumes that conscientious objection is protected, and the UK does not follow Canada in requiring all doctors and organisations to take part in assisted deaths.

It is not clear which drug or drug combination is most effective for bringing about a quick and peaceful assisted death. Oregon and Canada’s untested use of multiple drug mixtures should act as a warning to jurisdictions and clinicians considering the legalisation of assisted dying.

Footnotes

  • This article (with references) was first posted on BJGP Life on 28 Sep 2021; https://bjgplife.com/assisted

  • © British Journal of General Practice 2021
Back to top
Previous ArticleNext Article

In this issue

British Journal of General Practice: 71 (712)
British Journal of General Practice
Vol. 71, Issue 712
November 2021
  • Table of Contents
  • Index by author
Download PDF
Download PowerPoint
Email Article

Thank you for recommending British Journal of General Practice.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The impact on general practice of prescribing assisted dying drugs
(Your Name) has forwarded a page to you from British Journal of General Practice
(Your Name) thought you would like to see this page from British Journal of General Practice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The impact on general practice of prescribing assisted dying drugs
Claud Regnard, Carol Davis, Katherine Sleeman, Philip Williams, Ana Worthington
British Journal of General Practice 2021; 71 (712): 516. DOI: 10.3399/bjgp21X717605

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The impact on general practice of prescribing assisted dying drugs
Claud Regnard, Carol Davis, Katherine Sleeman, Philip Williams, Ana Worthington
British Journal of General Practice 2021; 71 (712): 516. DOI: 10.3399/bjgp21X717605
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • ADVERSE EVENTS
    • UNWILLING DOCTORS
    • Footnotes
  • Figures & Data
  • Info
  • eLetters
  • PDF

More in this TOC Section

  • A groundhog century? Collings and the crisis in general practice
  • How much does a GP cost?
  • Opening up the black boxes of our primary care systems
Show more Life & Times

Related Articles

Cited By...

Intended for Healthcare Professionals

BJGP Life

BJGP Open

 

@BJGPjournal's Likes on Twitter

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Current Issue
  • All Issues
  • Online First
  • Authors & reviewers

RCGP

  • BJGP for RCGP members
  • BJGP Open
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers

MY ACCOUNT

  • RCGP members' login
  • Subscriber login
  • Activate subscription
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP: research
  • Writing for BJGP: other sections
  • BJGP editorial process & policies
  • BJGP ethical guidelines
  • Peer review for BJGP

CUSTOMER SERVICES

  • Advertising
  • Contact subscription agent
  • Copyright
  • Librarian information

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7400
Email: journal@rcgp.org.uk

British Journal of General Practice is an editorially-independent publication of the Royal College of General Practitioners
© 2023 British Journal of General Practice

Print ISSN: 0960-1643
Online ISSN: 1478-5242